At a glance
| Meal-time examples | Lispro, aspart, glulisine |
|---|---|
| Basal examples | Glargine, degludec |
| Target | Insulin receptor |
| Major acute risk | Hypoglycemia |
| Other risk | Hypokalemia and medication errors |
Overview
This family includes rapid-acting analogs such as lispro, aspart and glulisine, and basal analogs such as glargine and degludec; detemir is another established basal analog. Each product has its own formulation, concentration and delivery compatibility. Insulin replaces or supplements a hormone that is essential for glucose regulation, particularly in type 1 diabetes. It is not a general muscle-building or anti-aging peptide. A family-level overview can explain common biology, but treatment decisions require the exact insulin, device, monitoring information and clinical context.
How it works
Insulin binds the insulin receptor and promotes glucose uptake in muscle and fat while suppressing hepatic glucose production. It also affects protein and lipid metabolism and shifts potassium into cells. Amino-acid changes and formulation technologies alter absorption and duration, producing meal-time or basal profiles. These pharmacokinetic differences are clinically consequential even though the medicines share the same fundamental receptor pathway.
Basal and meal-related roles
Basal insulin provides background action, while rapid-acting formulations address meal-related needs or other specifically prescribed roles. Pump, intravenous and subcutaneous permissions vary by product and concentration; they are not universal properties of every insulin analog.
How benefit is evaluated
Insulin trials assess glycemic control and hypoglycemia alongside practical treatment performance. A useful regimen balances glucose exposure against low-glucose events, rather than pursuing a single laboratory target without regard to safety and daily function.
Acute and local adverse effects
Hypoglycemia can be life-threatening. Potassium shifts can cause hypokalemia, and serious allergy can occur. Repeated use at the same site can produce lipodystrophy or localized amyloid deposits, altering absorption and glucose response.
Why concentration and device must be explicit
Different concentrations and pen systems create medication-error risks. Product labels warn against sharing pens and require particular handling when changing regimens. A nominal volume or a syringe marking is not a universal insulin-dose equivalence.
What a family record cannot replace
Meal patterns, physical activity, kidney or liver impairment and other medicines can change insulin requirements. This overview deliberately supplies pharmacology and safety context rather than an individualized regimen; the exact medicine and glucose data are necessary for prescribing decisions.
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Engineered insulin peptide hormones; multiple distinct medicines.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Humalog insulin lispro prescribing information ↗Regulatory source · Checked 2026-10-27
- Novo Nordisk: Tresiba insulin degludec prescribing information ↗Regulatory source · Checked 2026-10-27